Compare OBT & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBT | DNA |
|---|---|---|
| Founded | 1892 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 457.5M | 458.6M |
| IPO Year | 2021 | 2020 |
| Metric | OBT | DNA |
|---|---|---|
| Price | $37.48 | $7.83 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $36.00 | $8.50 |
| AVG Volume (30 Days) | 36.4K | ★ 1.1M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | 34.82 | ★ 46.49 |
| EPS | ★ 1.87 | N/A |
| Revenue | N/A | ★ $170,155,000.00 |
| Revenue This Year | $14.27 | N/A |
| Revenue Next Year | $7.99 | N/A |
| P/E Ratio | $20.41 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.25 | $5.37 |
| 52 Week High | $40.10 | $17.58 |
| Indicator | OBT | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.74 | 56.64 |
| Support Level | $35.50 | $7.16 |
| Resistance Level | $38.61 | $9.82 |
| Average True Range (ATR) | 1.25 | 0.40 |
| MACD | -0.03 | 0.14 |
| Stochastic Oscillator | 71.76 | 73.46 |
Orange County Bancorp Inc is a community bank holding company providing commercial and consumer banking services to individuals, small businesses, and local governments. It operates through two segments: Banking and Wealth Management. The Banking segment, the primary revenue driver, offers loans such as commercial real estate, construction, commercial & industrial, multifamily, and residential mortgages, along with services like cash management, escrow, deposits, ATMs, and digital banking. The Wealth Management segment provides investment management, trust services (trustee, administrator, custodian), and financial planning and advisory services to individuals and institutions.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.